SAGE-217

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Overweight rating for Sage but lowered the price target from $217 to $125. (See...

Shares of thinly-traded SAGE Therapeutics Inc NASDAQ: SAGE) are melting down after the company flunked in a late-stage trial of its lead CNS disorder drug candidate SAGE-217 in major depressive disorder, or MDD. What Happened To SAGE-217? Sage said its pivotal Phase 3 MOUNTAIN study evaluating...

Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) and SAGE Therapeutics Inc (NASDAQ: SAGE) were moving sharply higher Monday on separate clinical trial results.  Axsome's Major Depressive Disorder Drug Trial Axsome said its lead pipeline asset AXS-05 met its primary endpoint of...

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits. The stock moved mostly on sympathy for SAGE Therapeutics Inc (NASDAQ: SAGE), a biotech peer that released positive clinical data on its...